RIYADH, Saudi Arabia, Dec. 16, 2024 /PRNewswire/ -- On December 2nd, 2024, the 16th Conference of the Parties (COP16) to the United Nations Convention to Combat Desertification (UNCCD) kicked off in Riyadh, the capital of Saudi Arabia, which knows first-hand the impacts of desertification, land degradation and drought.
LONGi, the world's leading solar technology company, was invited to attend the side event hosted by the International Union for Conservation of Nature (IUCN) titled "Nature Positive Renewables as a Driver of Restoration" and the side event organized by Tsinghua University at the COP16 China Pavilion. Zhang Haimeng, Vice President and Chief Sustainability Officer of LONGi, delivered a speech via video at the side event, sharing LONGi's innovative practices and significant achievements in desertification control with the global community.
LONGi has always regarded sustainable development as a core strategy and actively promotes the application of green energy and desertification control. Zhang Haimeng detailed LONGi's achievements in the application of green technology and the prevention of desertification. He pointed out: "The impact of desertification is profound, with an estimated 45% of the global land surface affected by desertification, impacting 3.2 billion people, or one-third of the world's population. However, using just 1% of the global desert area for photovoltaic (PV) power generation could meet the electricity needs of all humanity; if 70% of the Earth's desert areas were transformed into oases, they could absorb all the carbon emissions produced by human activities."
As one of the effective means of desertification control, photovoltaic desertification control stands out in ecological improvement and windbreak and sand fixation. In the Kubuqi Desert, LONGi implemented the construction of two photovoltaic power stations of 336kW and 338kW, actively exploring green ecological development models such as "generating electricity on the panels, planting under the panels, and breeding between the panels," and has already solved many local desertification control challenges.
Zhang Haimeng introduced: "In desert areas, photovoltaic modules absorb sunlight, provide shade and reduce water evaporation during the day, and promote condensation at night. In addition, the water used to clean the solar panels can also effectively promote the survival and growth of vegetation." By combining photovoltaic systems with vegetation, not only is the stability of the solar power generation system improved, but the microclimate of the area is also significantly improved, effectively mitigating natural disasters such as hot winds, dry winds, and sandstorms.
LONGi has always been committed to improving the conversion efficiency of solar cells and reducing the levelized cost of electricity (LCOE) for photovoltaic power generation through the industrialization of advanced technologies. Zhang Haimeng said, "The concept of 'Solar for All' is applicable to various possible scenarios, making photovoltaic energy an affordable clean energy for everyone. From desert management to mine site restoration, from water supply in difficult areas to energy supply in future urban planning, the aim is to promote energy equity, green, and low-carbon transitions across various industries."
Zhang Haimeng called on global partners, policymakers, and the public to pay more attention to the importance of desertification prevention and control, and to draw experience from excellent environmental protection practices to accelerate the realization of a greener Earth. He emphasized: "LONGi is willing to work hand in hand with all parties to continuously promote the global desertification control cause to new heights."
About LONGi
Founded in 2000, LONGi is committed to being the world's leading solar technology company, focusing on customer-driven value creation for full scenario energy transformation.
Under its mission of 'making the best of solar energy to build a green world', LONGi has dedicated itself to technology innovation and established five business sectors, covering mono silicon wafers cells and modules, commercial & industrial distributed solar solutions, green energy solutions and hydrogen equipment. The company has honed its capabilities to provide green energy and has more recently, also embraced green hydrogen products and solutions to support global zero carbon development. www.longi.com
** The press release content is from PR Newswire. Bastille Post is not involved in its creation. **
LONGi shares its sustainable practices in combating desertification at COP16 in Riyadh, Saudi Arabia
SEOUL, South Korea, Dec. 16, 2024 /PRNewswire/ -- Harvest Integrated Research Organization (HiRO), a boutique global clinical research organization (CRO) providing cross-border clinical trial solutions, proudly announces the signing of a Memorandum of Understanding (MOU) with CHA University Bundang Medical Center (CBMC), a renowned medical institution in Seoul, South Korea.
In this strategic partnership, HiRO and CBMC are set to closely collaborate, delivering comprehensive solutions to global biotech and pharmaceutical companies across Phase I through Phase IV clinical trials. By leveraging their collective expertise, HiRO and CBMC are dedicated to streamlining clinical trial processes for optimal efficiency, fostering innovation, and driving advancements in healthcare research in the region and globally.
As a flagship hospital of the CHA Medical Group, one of South Korea's largest biomedical groups, CBMC is distinguished for its state-of-the-art medical services and robust research capabilities. CBMC's collaboration with HiRO will focus on providing valuable insights and support for clinical trials conducted at the center, spanning critical areas such as feasibility assessments, principal investigator selection, and the facilitation of patient recruitment processes. Correspondingly, HiRO will actively showcase the clinical research capabilities of South Korea and CBMC on global platforms, highlighting the exceptional facilities, skilled professionals, and research excellence of the region and the center.
Dr. Young-Sang Kim, Director of CHA Global Clinical Trials Center, underscored the significance of the collaboration, expressing, "Through our partnership with HiRO, we are poised to elevate our clinical research expertise and medical excellence. Drawing on HiRO's presence across the US, Europe, and the Asia-Pacific region, we are reinforcing our commitment to providing more effective and pioneering treatments on a global scale, ultimately improving outcomes for patients in need."
Dr. Karen Chu, Founder and CEO of HiRO, echoed this sentiment, expressing excitement about the partnership. She stated, "South Korea is a prime destination for clinical trials, with a robust healthcare infrastructure and favorable research environment. Our collaboration with CBMC represents a strategic alignment of our missions to provide top-notch services to our global clients and drive their innovation forward. We are confident that this partnership will further enhance our ability to offer capital-efficient and high-quality clinical trial solutions, leading to impactful results and significant advancements in medical breakthroughs."
Both organizations are enthusiastic about the prospects of their collaboration and are committed to exploring innovative avenues together. The signing of the MOU between HiRO and CHA Bundang Medical Center marks the beginning of a promising partnership to shape the future of clinical research in South Korea and beyond.
About Harvest Integrated Research Organization (HiRO)
Harvest Integrated Research Organization (HiRO) is a globally oriented, innovative clinical research organization (CRO). With global operations and integrated capabilities, HiRO provides a full range of cross-border solutions and services to its clients, including early pre-clinical strategic planning, clinical trial design, regulatory affairs, pharmacovigilance, statistics, data management, end-to-end project management, and clinical and medical monitoring services.
As an emerging global CRO, HiRO strives to become a market-leading, integrated global clinical research organization that works collaboratively with biotech and pharmaceutical companies to bring new products from the laboratory to the market, providing more effective solutions for patients worldwide. For more information on HiRO, please visit www.harvestiro.com.
About CHA University Bundang Medical Center (CBMC)
CHA University Bundang Medical Center (CBMC), established in 1995, is a leading medical institution in South Korea, renowned for its cutting-edge healthcare services, advanced research, and world-class medical expertise. As part of the CHA Medical Group, CBMC specializes in areas such as fertility treatment, oncology, regenerative medicine, and precision medicine. The center is equipped with state-of-the-art facilities and has earned international recognition for its contributions to both clinical care and medical research. CBMC remains committed to advancing global healthcare through innovation and collaboration. For more information on CBMC, please visit bundang.chamc.co.kr.
For media inquiries, please contact:
info@harvestiro.com
** The press release content is from PR Newswire. Bastille Post is not involved in its creation. **
HiRO Forges Strategic Partnership with CHA University Bundang Medical Center in South Korea
